Repligen Posts 68-Cent Loss Per Share in Third Quarter
RGEN sits 80% above its 52-week low of $100.99.
Summary
Repligen reported a third-quarter loss of $38.4 million, or 68 cents per share, a swing to red ink for the bioprocessing supplier, on revenue of $209.3 million. Adjusted EPS came in at USD 0.53 versus an IBES estimate of USD 0.46, and the company raised its FY26 revenue guidance to $844M-$852M, or 14.5%-15.5% reported growth, with adjusted EPS guidance of $2.05-$2.09. Context matters here: the company is mid-flight on its $1.5 billion acquisition of BioLife Solutions, which cleared HSR review in September and faces a BioLife stockholder vote that had been set for October 5, 2026.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — Repligen raised FY26 revenue guidance to $844M-$852M (14.5%-15.5% reported growth) and set adjusted EPS guidance of $2.05-$2.09.
At the time of this announcement, RGEN was trading at $181.38 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.4B. The 52-week trading range was $100.99 to $198.87. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.